Melissa Hackel - Infinity Pharmaceuticals Insider

INFI -- USA Stock  

USD 2.40  0.09  3.90%

Ms. Melissa Hackel serves as Vice President Finance of the Company. Melissa Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decisionmaking. Prior to joining Infinity, Ms. Hackel served as director of finance at Takeda Pharmaceutical Company. She received a MBA from Duke University and a B.A. in political science from Bates College.
  President Since 2017  MBA    

Management Efficiency

The company has return on total asset (ROA) of (28.6) % which means that it has lost $28.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (59.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 11 records


Robert JanssenDynavax Technologies Corporatio
Erik CheliusEndocyte
Michael BrinkleyEndocyte
David MozleyEndocyte
Michael OstrachDynavax Technologies Corporatio
Bradford MiddlekauffEdge Therapeutics
Alyssa WyantEdge Therapeutics
David JohnsonDynavax Technologies Corporatio
Katherine ParkerEndocyte
Kevin LaliberteDova Pharmaceuticals
Theodore AshburnDicerna Pharmaceuticals

Entity Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 22 people.Infinity Pharmaceuticals (INFI) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 22 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Infinity Pharmaceuticals Leadership Team

Joseph Pearlberg, Vice President - Clinical Development
Melissa Hackel, Vice President - Finance
William Bertrand, Executive Vice President General Counsel
Vito Palombella, Chief Scientific Officer and Executive VP
Jeffrey Berkowitz, Independent Director
Lawrence Bloch, CFO, Executive Vice President Chief Business Officer
Norman Selby, Lead Outside Independent Director
Jose Baselga, Independent Director
Samuel Agresta, Chief Medical Officer
Michael Venuti, Independent Director
Michael Kauffman, Independent Director
Eric Lander, Independent Director
David Beier, Independent Director
Julian Adams, President of RandD
Anthony Evnin, Independent Director
Gwendolyn Fyfe, Independent Director
Sujay Kango, Executive Vice President Chief Commercial Officer
Ian Smith, Independent Director
Adelene Perkins, Chairman of The Board, CEO and Pres

Stock Performance Indicators

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Headlines Timeline

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.